EXEL (Exelixis) Operating Margin %: 39.51% (As of Jun. 2026) — 53% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EXEL Exelixis Inc EXEL
88 GF Score
Price $53.69
GF Value $45.73
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Exelixis Operating Margin %?

Exelixis EXEL -1.31% 88 Operating Margin % is 39.51% as of Jun. 2026, which is 53% above its 10-year median of 25.90. GuruFocus rates EXEL with a GF Score™ of 88/100 and a GF Value™ of $45.73 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 944 Biotechnology companies, Exelixis ranks better than 95.55% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Exelixis's Operating Income for the three months ended in Jun. 2026 was $248 Mil. Exelixis's Revenue for the three months ended in Jun. 2026 was $629 Mil. Therefore, Exelixis's Operating Margin % for the quarter that ended in Jun. 2026 was 39.51%.

Good Sign:

Exelixis Inc operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for Exelixis's Operating Margin % or its related term are showing as below:

EXEL' s Operating Margin % Range Over the Past 10 Years
Min: -14.21   Med: 25.9   Max: 51.4
Current: 40.73


EXEL's Operating Margin % is ranked better than
95.55% of 944 companies
in the Biotechnology industry
Industry Median: -84.515 vs EXEL: 40.73

Exelixis's 5-Year Average Operating Margin % Growth Rate was 23.20% per year.

Exelixis's Operating Income for the three months ended in Jun. 2026 was $248 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was $992 Mil.


Exelixis  (NAS:EXEL) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Exelixis Operating Margin % Related Terms


Exelixis Operating Margin % Historical Data

* Premium members only.

The historical data trend for Exelixis's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exelixis Operating Margin % Chart

Exelixis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.98 12.51 9.34 31.81 38.48

Exelixis Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.58 42.89 39.41 41.15 39.51

EXEL vs MDGL, AXSM, ARWR: Operating Margin % Comparison

For the Biotechnology subindustry, Exelixis's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exelixis Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exelixis's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Exelixis's Operating Margin % falls into.


EXEL
88GF Score
Exelixis Inc EXEL
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Exelixis Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Exelixis's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=892.701 / 2320.126
=38.48 %

Exelixis's Operating Margin % for the quarter that ended in Jun. 2026 is calculated as

Operating Margin %=Operating Income (Q: Jun. 2026 ) / Revenue (Q: Jun. 2026 )
=248.414 / 628.69
=39.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 39.51% mean?
Exelixis (EXEL) has a Operating Margin % of 39.51% as of Jun. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Exelixis and its competitors. This is 53% above median its historical median of 25.90. According to the industry distribution chart, Exelixis ranks #42 out of 944 companies in the Biotechnology industry, placing it in the top 4.4%.
Is Exelixis' Operating Margin % too high?
Exelixis' current Operating Margin % of 39.51% is 53% above median its 10-year median of 25.90. Based on the distribution chart, Exelixis ranks #42 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Exelixis has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Exelixis' Operating Margin % compare to MDGL and AXSM?
According to the Biotechnology industry distribution chart, Exelixis ranks #42 out of 944 companies for Operating Margin %. This places Exelixis in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Exelixis and its competitors. Exelixis's current Operating Margin % is 39.51%, which is 53% above median its own 10-year median of 25.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exelixis stock overvalued right now?
Based on GuruFocus' analysis, Exelixis (EXEL) is currently considered Modestly Overvalued. The stock's GF Value™ is $45.73, compared to a current price of $53.69 — trading 17.4% above its estimated fair value. The current Operating Margin % is 39.51%, which is 53% above median its 10-year median of 25.90. Exelixis' overall GF Score™ is 88/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Exelixis (EXEL), the current Operating Margin % is 39.51% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Exelixis (EXEL) Overvalued in 2026?

Based on GuruFocus' analysis, Exelixis stock appears to be overvalued. The current stock price of $53.69 is trading 17.4% above its estimated GF Value™ of $45.73. GuruFocus considers Exelixis to be Modestly Overvalued.

Key valuation signals for EXEL:

  • Operating Margin %: 39.51% (53% above median its 10-year median of 25.90)
  • GF Value™: $45.73 vs. price of $53.69 (17.4% above fair value)
  • GF Score™: 88/100 with 4 warning signs

No single metric tells the full story. See the EXEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Exelixis Business Description

Address 1851 Harbor Bay Parkway, Alameda, CA, USA, 94502
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
88GF Score

Get the complete analysis for EXEL

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$53.69
Price
$45.73
GF Value